Altasciences is supporting Alzamend Neuro, Inc. in advancing a novel treatment for dementia related to Alzheimer’s disease. In addition to having conducted Alzamend’s Phase IIa multiple ascending dose (MAD) clinical trial in healthy subjects, Altasciences is continuing to provide clinical monitoring, project management, biostatistics, pharmacokinetics (PK), bioanalysis, and medical writing solutions as the product candidate is evaluated in Alzheimer’s patients. The purpose of the MAD study co...